Introduction
Advancement in genetic engineering, the availability of better immunosuppressive agents and antimicrobials, and better supportive care and understanding of stem cell biology and mobilization techniques made SCT a reality in countries with limited resources. 1 In countries such as Pakistan, high population density, consanguineous marriages and environmental factors result in an increasing number of cases of fatal genetic disorders such as b-thalassemia major and acquired idiopathic aplastic anemia diagnosed each year. 1 Hematological malignancies pose another real challenge to the precarious health-care system of the country. Despite the rich human and natural resources, the health indicators are not encouraging (Figure 1 ).
Pakistan has a population of 165 million (2006 estimate). the population growth rate is 2.1%, birth rate is 29.7/1000, infant mortality rate is 70.5/1000, life expectancy is 63.4, and density per square mile is 551. Gross national income per capita (PPP international $) is 2350. Life expectancy at birth M/F (years) is 61/62, healthy life expectancy at birth M/F (years, 2002) is 54/52, probability of dying under 5 years of age (per 1000 live births) is 100, probability of dying between 15 and 60 years of age M/F (per 1000 population) is 232/212, total expenditure on health per capita (International $, 2004 ) is 48, and total expenditure on health as % of GDP (2004) is 2.2.
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The geographic area of coverage (patient referral)-three centers covers almost the whole country. Patients from Afghanistan and expatriates from the Middle East are also referred for treatment. Bismillah Taqee Institute of Health Sciences (BTIHS) gets 50% of patients from Karachi, whereas the other 50% are from remaining Sindh, Balochistan, southern Punjab and Afghanistan. The Armed Forces Bone Marrow Transplant Center mainly gets patients from the armed forces personnel and their dependants, North West Frontier Province (NWFP) and remaining Punjab. 4 Number of transplantation centers and types of transplantations performed by each center Currently, there are three active transplant centers engaged in stem cell transplant. Mainly allogeneic procedures are carried out. Surprisingly, autologous procedures are very few in number. This is in sharp contrast to the rest of the world where autologous transplants are predominant. This is probably due to the lack of awareness among oncologists who mainly treat lymphomas and myeloma and do not stratify patients, and referral is late and few.
Approximate total number of transplantations performed per year
Altogether, since the last 3 years, 70-75 transplants have been carried out each year in three centers. The predominant type of transplantation performed included sibling donor availability vs alternate donor programs. BTIHS performs allogeneic PBSC transplant in essentially all cases, whereas the Armed Forces Bone Marrow Transplant Center and Aga Khan University (AKU) preferentially use bone marrow as a source of stem cells keeping PBSC as a backup. 4, 5 Sibling donor program is in place. Matched unrelated program is not developed. National marrow donor registry is missing. There is a male predominance, that is, male-to-female ratio is 3:1. The majority of patients are young adults under the age of 30 years. The conditioning regimen used is chemotherapy based. None of the centers is using radiation for conditioning. Cyclosporin and short course of methotrexate is used for graft-versus-host disease (GVHD) prophylaxis. BTIHS uses only cyclophosphamide for conditioning in aplastic anemia, whereas the Armed Forces Bone Marrow Transplant Center and AKU add ALG. For other indications, busulphan/cyclophosphamide is the main conditioning protocol (Figure 2 ).
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Distribution of disease entities and prevalent diseases being transplanted
Pakistan is among those countries where the prevalence of aplastic anemia is high. In our center, in the last 5 years, over 350 new patients were diagnosed or treated. The majority of them were young males from a rural population without any history of exposure to drugs or infections. The results of allogeneic stem cell transplant are gratifying in this indication. 6 b-Thalassemia is the most common genetic disorder in Pakistan; its prevalence is estimated to be 5-8%. A total of 5000 new cases are diagnosed each year. 7 Blood transfusion improves their vitality but it takes its toll. Iron continues to be deposited owing to repeated blood transfusion. Iron damages the liver, heart and glands. These transfused children die around 10-12 years of age owing to heart failure and chronic liver disease caused by Hepatitis B & C viral infections. Prevention of thalassemia is the only way to control the major public problem. 7 The emphasis should be to educate parents of affected children regarding antenatal diagnosis, importance of comprehensive care and significance of iron chelation therapy and BMT. BMT in b-thalassemia major is rewarding countries such as Pakistan with a high prevalence of the thalassemia gene, and BMT/PBSCs hold the potential as a curative therapy. 8, 9 Half of all patients are those with aplastic anemia, 25% those with b-thalassemia, whereas the remaining patients are those with hematological malignancies.
Special observations regarding transplantation
Despite using PBSC at BTIHS, acute and chronic GVHD incidence is very low. Extensive chronic GVHD is seen in 4% cases only; localized GVHD is seen in 11% of cases in all three centers. Post-transplant malignancies and other late effects are yet to come, as the transplant program is relatively new. 4, 5 Infectious disease issues related to transplantation in specific geographic areas Hundred percent donor-recipient pairs are CMV-IgGpositive. Overall, CMV reactivation is low; only 2% of cases are documented as CMV infection. BTIHS does not use antituberculosis (TB) prophylaxis; only two patients developed TB while on immunosuppression, whereas four patients developed it months after stopping it. Two other centers use isoniazid (INH) prophylaxis; the Armed Forces Bone Marrow Transplant Center had four cases developing TB in a series of the first 30 cases when they change their policy of initiating INH prophylaxis. Five of their patients developed TB after stopping immunosuppression and INH. 10, 11 In none of our patients was Hepatitis C virus (HCV) reactivation observed, and neither did they progress to acute liver disease. Rather, in four cases, HCV RNA disappeared after 1 year of transplant, whereas in the remaining 10, there is no change. Transfusion-transmitted malaria is another problem that we encountered during the early transplant period. It transpires that it was due to poor malaria laboratory screening of asymptomatic blood donors.
Transplant outcome
For aplastic anemia, treatment-related mortality is 6% and for thalassemia it is 22%, whereas for hematological malignancies it is 18%. Long-term survival is as follows: for aplastic anemia, it is 74%, for thalassemia it is 72% and for hematological malignancies it is 54%. [4] [5] [6] 12, 13 Causes of mortality include acute GVHD, sepsis, relapse, hepatic venoocclusive disease, fungal infection and multiorgan failure. 4, 5 Approximate cost of transplantation, cost to patient and type of coverage for human SCT The average cost of transplant for aplastic anemia and thalassemia is US$22 000. In hematological malignancies, for good-risk patients, it is US$25 000-27 000, whereas in highrisk patients, it is US$30 000-35 000. Autologous PBSC transplantation cost is US$18 000.
1 This is 10-20 times less than the cost in Europe and USA. Developing this specialty in the country could save precious foreign exchange and provide a life-saving treatment modality. Despite being cheaper locally, the cost of BMT in Pakistan is still prohibitive for the majority of patients. The government cannot support such an expensive treatment program. A troika of NGOs, philanthropists and the government can evolve a partnership to support the BMT program in the country. 1, 4 Obstacles in the performance of transplantation Because of very low income and economic factors, a vast majority of families cannot afford it. Only a minority of patients who are covered by health insurance can get it done. At BTIHS, various individuals support almost all transplants through philanthropic donations. Because of the relatively larger family size, sibling donors are found in almost 60-70% of cases. The low literacy rate, lack of awareness about the program, financial hardship, lack of civic infrastructure and high rate of infection are some of the obstacles in the growth of the program, with 40% of the population below the poverty line.
1,2 The lack of health insurance, high cost of drugs, difficulty in follow up and lack of social workers and rehabilitation support are some other issues faced by transplant centers. Poor hygiene, water supply and poor sanitation are other problems being faced. 1 
Participation in international registries
All three centers participate in the Centre for International Bone Marrow Transplant Registry (CIBMTR). As to research activities in transplantation at BTIHS, our emphasis is on febrile neutropenia, GVHD and chimerism studies.
Summary
In Pakistan, the transplant program is only a decade old. Allogeneic transplant activity is now established for aplastic anemia and thalassemia, but the autologous program needs to be promoted to treat lymphoma and myeloma (Figure 3) . Despite its lower cost, its benefits are not reaching the common man because of the poor healthcare system. Endemicity of malaria, TB and hepatitis B and C pose a special challenge to transplant teams. The national marrow donor registry and cord blood banks are areas that need attention. Any such program needs government patronage; so far, there is no government support available for the stem cell transplant program. 
